GALT
Galectin Therapeutics Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
3.70
▲ 0.13 (3.64%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.00
Prev close
3.57
Day high
3.74
Day low
3.59
Volume
174.89K
Market cap
—
P/E (TTM)
—
52W range
2.03 – 7.13
Free account
3 more panels on GALT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $14.29M | $36.57M | $32.13M | $31.74M | -60.9% |
| Selling, general & admin | $5.79M | $5.86M | $5.94M | $6.62M | -1.1% |
| Total operating expense | $20.09M | $42.43M | $38.07M | $38.35M | -52.7% |
| Operating income | -$20.09M | -$42.43M | -$38.07M | -$38.35M | +52.7% |
| Net interest income | -$7.20M | -$5.20M | -$2.56M | -$981.00K | -38.5% |
| Pre-tax income | -$30.84M | -$47.05M | -$41.07M | -$38.78M | +34.5% |
| Net income | -$30.84M | -$47.05M | -$41.07M | -$38.78M | +34.5% |
| Net income to common | -$30.97M | -$47.20M | -$44.80M | -$38.87M | +34.4% |
| Basic EPS | -0.48 | -0.76 | -0.74 | -0.65 | +36.8% |
| Diluted EPS | -0.48 | -0.76 | -0.74 | -0.65 | +36.8% |
| EBIT | -$23.51M | -$41.51M | -$38.27M | -$37.74M | +43.4% |
| EBITDA | -$23.45M | -$41.47M | -$38.24M | -$37.71M | +43.4% |
| Basic shares | 63.90M | 62.31M | 60.16M | 59.39M | +2.6% |
| Diluted shares | 63.90M | 62.31M | 60.16M | 59.39M | +2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $17.72M | $15.12M | $25.66M | $18.59M | +17.2% |
| Cash & short-term investments | $17.72M | $15.12M | $25.66M | $18.59M | +17.2% |
| Total current assets | $19.44M | $17.25M | $27.71M | $20.55M | +12.7% |
| Property, plant & equipment | $0 | $0 | $0 | $0 | — |
| Total assets | $19.53M | $17.50M | $28.20M | $21.29M | +11.6% |
| Total current liabilities | $8.03M | $35.41M | $15.68M | $13.01M | -77.3% |
| Current debt | — | $21.12M | — | — | — |
| Long-term debt | $133.74M | $85.11M | $71.74M | $39.83M | +57.1% |
| Total debt | $133.76M | $106.25M | $71.79M | $39.87M | +25.9% |
| Total liabilities | $145.73M | $120.56M | $88.44M | $53.48M | +20.9% |
| Retained earnings | -$432.55M | -$401.57M | -$354.37M | -$309.57M | -7.7% |
| Shareholder equity | -$126.19M | -$103.07M | -$60.24M | -$32.19M | -22.4% |
| Working capital | $11.41M | -$18.16M | $12.03M | $7.54M | +162.8% |
| Net tangible assets | -$126.19M | -$103.07M | -$60.24M | -$32.19M | -22.4% |
| Shares issued | 65.20M | 63.16M | 61.85M | 59.43M | +3.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$30.84M | -$47.05M | -$41.07M | -$38.78M | +34.5% |
| Depreciation & amortisation | $53.00K | $37.00K | $33.00K | $32.00K | +43.2% |
| Stock-based compensation | $1.66M | $2.45M | $2.26M | $2.87M | -32.2% |
| Change in working capital | $609.00K | $2.28M | $4.68M | $4.97M | -73.3% |
| Operating cash flow | -$23.88M | -$41.77M | -$32.97M | -$31.06M | +42.8% |
| Investing cash flow | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $26.48M | $31.23M | $40.03M | $10.00M | -15.2% |
| Free cash flow | -$23.88M | -$41.77M | -$32.97M | -$31.06M | +42.8% |
| End cash position | $17.72M | $15.12M | $25.66M | $18.59M | +17.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $2.23M | $1.93M | $2.61M | $3.26M | $6.49M | +15.4% |
| Selling, general & admin | $1.85M | $1.43M | $1.59M | $1.36M | $1.41M | +28.9% |
| Total operating expense | $4.08M | $3.37M | $4.20M | $4.63M | $7.90M | +21.2% |
| Operating income | -$4.08M | -$3.37M | -$4.20M | -$4.63M | -$7.90M | -21.2% |
| Net interest income | -$1.95M | -$1.91M | -$1.78M | -$1.80M | -$1.71M | -2.0% |
| Pre-tax income | -$5.05M | -$5.50M | -$8.18M | -$7.52M | -$9.63M | +8.3% |
| Net income | -$5.05M | -$5.50M | -$8.18M | -$7.52M | -$9.63M | +8.3% |
| Net income to common | -$5.07M | -$5.56M | -$8.22M | -$7.58M | -$9.61M | +8.9% |
| Basic EPS | -0.08 | — | -0.13 | -0.12 | -0.15 | — |
| Diluted EPS | -0.08 | — | -0.13 | -0.12 | -0.15 | — |
| EBIT | -$3.06M | -$3.56M | -$6.36M | -$5.70M | -$7.89M | +14.1% |
| EBITDA | -$3.05M | -$3.52M | -$6.36M | -$5.69M | -$7.88M | +13.5% |
| Basic shares | 65.78M | — | 64.20M | 63.45M | 63.20M | — |
| Diluted shares | 65.78M | — | 64.20M | 63.45M | 63.20M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $14.11M | $17.72M | $11.53M | $13.77M | $7.43M | — | -20.4% |
| Cash & short-term investments | $14.11M | $17.72M | $11.53M | $13.77M | $7.43M | — | -20.4% |
| Total current assets | $15.69M | $19.44M | $12.73M | $15.43M | $9.29M | — | -19.3% |
| Property, plant & equipment | — | $0 | — | — | — | $0 | — |
| Total assets | $15.76M | $19.53M | $12.87M | $15.60M | $9.53M | — | -19.3% |
| Total current liabilities | $7.31M | $8.03M | $136.44M | $10.77M | $110.84M | — | -9.0% |
| Current debt | — | — | $122.28M | — | $97.11M | $21.12M | — |
| Long-term debt | $135.71M | $133.74M | — | $120.46M | $10.81M | $85.11M | +1.5% |
| Total debt | $135.72M | $133.76M | $122.31M | $120.51M | $107.99M | — | +1.5% |
| Total liabilities | $146.00M | $145.73M | $138.17M | $132.77M | $121.79M | — | +0.2% |
| Retained earnings | -$437.61M | -$432.55M | -$426.98M | -$418.76M | -$411.18M | — | -1.2% |
| Shareholder equity | -$130.24M | -$126.19M | -$125.30M | -$117.17M | -$112.26M | — | -3.2% |
| Working capital | $8.38M | $11.41M | -$123.72M | $4.65M | -$101.56M | — | -26.5% |
| Net tangible assets | -$130.24M | -$126.19M | -$125.30M | -$117.17M | -$112.26M | — | -3.2% |
| Shares issued | 65.86M | 65.20M | 64.47M | 64.06M | 63.29M | — | +1.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$5.05M | -$5.50M | -$8.18M | -$7.52M | -$9.63M | +8.3% |
| Depreciation & amortisation | $12.00K | $41.00K | $0 | $2.00K | $10.00K | -70.7% |
| Stock-based compensation | $686.00K | $195.00K | $496.00K | $500.00K | $468.00K | +251.8% |
| Change in working capital | $1.31M | -$1.18M | $1.73M | -$1.03M | $1.09M | +210.8% |
| Operating cash flow | -$3.87M | -$6.04M | -$3.54M | -$6.60M | -$7.69M | +36.0% |
| Financing cash flow | $257.00K | $12.24M | $1.30M | $12.94M | $0 | -97.9% |
| Free cash flow | -$3.87M | -$6.04M | -$3.54M | -$6.60M | -$7.69M | +36.0% |
| End cash position | $14.11M | $17.72M | $11.53M | $13.77M | $7.43M | -20.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
GlobeNewswire · 9d ago
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
GlobeNewswire · 19d ago
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Zacks · 60d ago
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial
Stocktwits · 60d ago
Galectin Therapeutics Says FDA Alignment Reached on Phase 3 Belapectin Trial
MT Newswires · 61d ago
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
GlobeNewswire · 61d ago
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
GlobeNewswire · 88d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.